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Abstract
Type 2 Maturity Onset Diabetes of the Young (MODY2) is a monogenic autosomal disease characterized by a primary defect
in insulin secretion and hyperglycemia. It results from GCK gene mutations that impair enzyme activity. Between 2006 and
2010, we investigated GCK mutations in 66 diabetic children from southern Italy with suspected MODY2. Denaturing High
Performance Liquid Chromatography (DHPLC) and sequence analysis revealed 19 GCK mutations in 28 children, six of which
were novel: p.Glu40Asp, p.Val154Leu, p.Arg447Glyfs, p.Lys458_Cys461del, p.Glu395_Arg397del and c.580-2A.T. We
evaluated the effect of these 19 mutations using bioinformatic tools such as Polymorphism Phenotyping (Polyphen), Sorting
Intolerant From Tolerant (SIFT) and in silico modelling. We also conducted a functional study to evaluate the pathogenic
significance of seven mutations that are among the most severe mutations found in our population, and have never been
characterized: p.Glu70Asp, p.His137Asp, p.Phe150Tyr, p.Val154Leu, p.Gly162Asp, p.Arg303Trp and p.Arg392Ser. These seven
mutations, by altering one or more kinetic parameters, reduced enzyme catalytic activity by .40%. All mutations except
p.Glu70Asp displayed thermal-instability, indeed .50% of enzyme activity was lost at 50uC/30 min. Thus, these seven
mutations play a pathogenic role in MODY2 insurgence. In conclusion, this report revealed six novel GCK mutations and
sheds some light on the structure-function relationship of human GCK mutations and MODY2.
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Introduction
Maturity Onset Diabetes of the Young (MODY), a monogenic
diabetes inherited in an autosomal dominant mode, accounts for
1–2% of all diabetes forms in Europe [1,2]. It is a clinically
heterogeneous group of diseases caused by at least eight gene
defects in the pancreatic b-cell that impair insulin secretion [3].
MODY is characterized by onset before 25 years of age; patients
usually lack auto-antibodies, and clinical manifestations go from
slight non-ketotic hyperglycemia to severe complicated hypergly-
cemia [4]. Heterozygous mutations in the glucokinase (GCK) gene
produce two distinct diseases, MODY type 2 (MODY2)
(MIM:125851) and persistent hyperinsulinemia of infancy
(MIM:601820) [5,6]. Persistent hyperinsulinemia of infancy is
associated with hyperactive GCK variants, while MODY2 is
associated with GCK mutations that impair its activity [7]. GCK
(hexokinase IV) catalyzes the ATP-dependent phosphorylation of
glucose in the first, rate-limiting step of glycolysis in pancreatic b-
cells [1]. The crystal structure determination of the enzyme by
Kamata et al. [8] revealed that the enzyme exists in at least two
distinct forms, the super-open ligand-free form and the closed
active form that is bound to glucose and ATP. The molecule
consists of two domains, namely a small and large domain
separated by the glucose site. In detail, amino acid residues 1–64
and 206–439 belong to the large domain, amino acid residues 72–
201 and 445–465 to the small domain, and amino acid residues
65–71, 202–205 and 440–444 to the three loops connecting the
domains [8]. The GCK protein switches from an inactive
conformation to a close active conformation upon ligand binding.
A huge conformational transition occurs through a large rotation
of the small domain [8].
The heterozygous loss-of-function GCK mutations causative of
MODY2 diabetes include missense, nonsense, splicing, small
deletions/insertions/duplications variants, and result in stable
fasting hyperglycemia from birth (.5.5 mol/L) and rare micro-
vascular complications [1]. Over 644 GCK mutations have been
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38906described, and a study of the mutational mechanisms for a number
of these has shed light on GCK regulation [9].
The molecular diagnosis of MODY2 is important: to classify the
type of diabetes correctly, to predict prognosis, and to initiate
screening of family members [1]. It is particularly important to
identify MODY2 in diabetic pregnant patients in order to start
‘‘ad hoc’’ treatment [10]. However, the identification of GCK
mutations by molecular analysis will not always reveal whether a
variant is really pathogenic or how serious the diabetic phenotype
could be. Therefore, in this five-year study, we applied an
integrated approach to investigate the effect of GCK mutations in
the diabetic phenotype in children from southern Italy. First, we
used DHPLC and mutation sequencing to identify variants, then a
computational approach to predict the effect of the variants
identified, and finally a functional study to determine the effect of
seven candidate variants on enzyme activity and on enzyme
thermo-stability.
Results
Among the 66 enrolled patients with suspected MODY2, 28/66
were diagnosed as MODY2 based on mutations in the GCK gene
(MODY2+) and 38/66 were MODY2-negative (MODY22). All
mutated patients were unrelated, except two pairs of siblings
(patient identification: MD19/20: two sisters and MD69/70:
brother/sister). The mean age at diagnosis (6 Standard Deviation:
SD) was lower, albeit not significantly, in MODY2+ than in
MODY22 patients (105645 months vs 113645 months). Mean
triglyceride levels did not differ between the two groups (0.660.2
and 0.760.3 mmol/L, respectively). Mean Fasting Plasma Glu-
cose (FPG) and glycosylated hemoglobin (HbA1c) concentrations
were significantly higher (p,0.003 and p,0.001, respectively) in
MODY2+ than in MODY22 patients (6.760.8 mmol/L and
6.260.3% vs 6.160.7 mmol/L and 5.560.5%, respectively). The
Body Mass Index zeta-score (BMIz-score) of enrolled children at
first admission was always in the reference range for the children’s
age (reference range: 21.5/+1.5), except in one patient (BMIz-
score: 2.5). Two/28 MODY2+ patients were positive for only one
type-1 diabetes auto antibody (glutamate decarboxylase: 8 and
18 U/mL). The patients were untreated until diagnosis.
Identification of GCK Mutations
We identified 19 different GCK mutations in 28/66 patients
(Table 1). Six of them were novel: two missense mutations
(p.Val154Leu and p.Glu40Asp), one splice site variant (c.580-
2A.T) and three deletions (p.Lys458_Cys461del, p.Arg447Glyfs,
and p.Glu395_Arg397del). We also found 13 previously reported
mutations: 11 missense mutations (p.Arg303Trp, p.Gly261Arg,
p.Phe150Tyr, p.Ala259Thr, p.Glu70Asp, p.Lys420Glu,
p.Ala188Thr, p.Tyr289Cys, p.Asp278Glu, p.Gly223Ser, and
p.Ala449Thr) and two splice site variants (c.864-1G.A and
c.1019+5G.A). All the detected mutations were always present in
the children’s mother or father and were absent from 200
chromosomes of our euglycemic controls. Seven mutations were
each present in two unrelated families: p.Arg303Trp, p.Lys458_-
Cys461del, p.Arg447Glyfs, p.Gly261Arg, p.Phe150Tyr, p.Lys420-
Glu and p.Ala259Thr, the latter was also identified in two siblings.
The splice variant c.580-2A.T was present in two siblings.
Table 1 shows, for each mutation (except the three splice variants
c.864-1G.A, c.580-2A.T and c.1019+5G.A, the frameshift
mutation p.Arg447Glyfs and the p.Lys458_Cys461del), the
nucleotide position, the amino acid change (if present), the effect
on the protein predicted by bioinformatics.
Bioinformatics Study of the GCK Variants
All substitutions, except p.Val154Leu and p.Glu40Asp, were
predicted to be deleterious mutations by online prediction tools
(Table 1, column 4). Overall, the theoretical structural models of
the mutants we obtained in silico (Table 1, column 5), preserve the
overall protein fold. In detail, however, all mutations produced
local conformational alterations 2 in some cases, such as
p.Gly162Asp, dramatic perturbations – that well account for the
functional alterations we found (Table 2). p.Arg303Trp-Arg303
is a highly conserved residue located in the a8 helix within the
large domain. Mutation p.Arg303Trp disrupts two salt-bridges
between the side chain of Arg303 and the side chain of Glu300,
located in the same helix. These salt-bridges may be essential for
the stability of the helix and their loss could destabilize the helix
structure. p.Val154Leu-The p.Val154Leu mutation (Figure 1)
does not cause any significant change in the local structure.
Indeed, Val154 is located in the b-sheet that encompasses the
small domain hydrophobic core. Its substitution with a leucine
residue does not affect the hydrophobic interactions. Nevertheless,
Val154 is involved in the large conformational variation from the
super-open to close form upon glucose binding (Figure 1A).
p.Gly261Arg-Gly261 is located in the loop connecting the b-
sheet and the a6 helix in the large domain. p.Gly261Arg is a
dramatic mutation because the small, flexible hydrophobic Gly
residue is replaced by a very large Arg residue that bears a positive
net charge. This substitution causes a local re-arrangement that
involves the nearby residues such as Leu266 and Leu270. This
process results in destabilization of the local structure.
p.Phe150Tyr-Phe150 is a highly conserved residue located in
the b-sheet that encompasses the small domain hydrophobic core.
The p.Phe150Tyr mutation (Figure 1B, C) introduces a polar
residue inside the hydrophobic core in a region rich in
phenylalanine. This replacement can influence the stability of
the b-sheet thereby altering the structure of the domain.
p.Ala259Thr-Ala259 residue is located in the large domain near
the glucose-binding cleft. Introduction of a larger and polar side
chain of threonine in the p.Ala259Thr mutant could influence the
hydrogen bond network in that area. In fact, Thr259 can compete
with other residues in the formation of hydrogen bonds with two
water molecules. See our previous study for a description of the
p.Glu70Asp variant [11]. p.Lys420Glu-Mutation p.Lys420Glu
involves an inversion from a positively charged lysine to a
negatively charged glutamic acid. The substitution affects the
interaction of Lys420 with surrounding residues. Indeed, Lys420 is
located in the a12 helix (Figure S1) in the large domain and forms
a salt bridge with Glu440 located in a connecting loop between the
two domains. The loss of this bond, caused by the mutation, could
destabilize the region. p.Ala188Thr-The p.Ala188Thr mutation
alters a highly conserved amino acid. Ala188 is located in the a4
helix within the small domain. The mutation leads to the
substitution of a hydrophobic residue, alanine, with a polar
residue, tyrosine, on the hydrophobic side of an amphipathic helix.
Thr188 can form hydrogen bonds through the hydroxyl group
with the side chains of the Ser127 and Asp124 residues on the a3
helix that is on the surface of the enzyme. The introduction of the
threonine can cause a different arrangement of such side chain.
p.Tyr289Cys-Tyr289 is located in the a7 helix in the large
domain. The substitution of the bulk tyrosine in position 289 with
the smaller cysteine side chain leads to the formation of a cavity.
The mutant disrupts a favorable interaction between Tyr289 and
Met381 of the a11 helix that may be important to keep helices
together. It is noteworthy that, in our model, Cys289 is not bound
to the nearby Cys230 because the distance (4.1 A ˚) between the two
sulfur atoms too long for a disulfide bond formation. p.As-
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amino acid. Asp278 is located on the polar side of the a6 helix in
the large domain. The replacement of Asp with a Glu residue in
the mutant does not seem to cause significant changes in the
enzyme structure. p.Gly223Ser-Gly223 is a highly conserved
residue located in the b-sheet of the large domain hydrophobic
core. The substitution with a serine involves the serine side-chain
hydrogen bonding to Cys 233, close to Gly223 in the structure of
GCK and could perturb the b-strand. p.Glu40Asp-The
pGlu40Asp mutation substitutes a conserved glutamate residue
with aspartate. Glu40 is located on the polar side of the a2 helix in
the large domain. These amino acids are acidic residues but the
side chain of the aspartate is shorter than the side chain of the
glutamate. Nevertheless, the mutation does not seem to cause
significant changes in the structure of the enzyme. p.Ala449Thr-
Ala449 is a highly conserved residue located on the C-terminal
a13 helix. This helix is part of the small domain in the closed form,
but it lies between the two domains in the super-open form. In the
closed form, the small domain has a three-layer architecture and
the a13 helix is in the inner layer. At the domain interface, the a13
helix makes favorable interactions with the a5 helix of the large
domain. Because the conformational features of this region are
essential for the super-open (inactive form)/closed (active form)
conversion, the introduction of a larger and polar side chain of the
threonine in the p.Ala449Thr mutant could influence the
enzymatic activity and/or stability. p.Glu395_Arg397del–The
p.Glu395_Arg397 deletion causes the elimination of the last
residue, Glu395, of the a11 helix in the large domain and two
residues of the following loop, Ser396 and Arg397. In the wild-
type enzyme, Glu395 is involved, through the backbone N atom,
in the formation of a hydrogen bond of the a11 helix. Its deletion
in the mutant causes the lack of this bond and could destabilize the
C-terminal region of the helix. Moreover, also the backbone N
atom of Arg397 interacts with an oxygen atom of Arg394 thereby
Table 1. GCK mutations detected in MODY2 children from South Italy.
Patient
code
GCK
Exon
a
cDNA
mutation
b
Polyphen/SIFT
prediction
c
Aminoacid change
d/Domain
localization/Secondary structure Effect on protein 3D-structure Reference
MD01/92 8 c.907C.T 1/deleterious p.Arg303Trp/Large domain/a8 helix Disruption of two salt-bridges [25]
MD05/71 10 c.1373_1385del p.Lys458_Cys461del/Small domain/
a13 helix
NOVEL
MD10 4 c.460G.T 2/tolerated p.Val154Leu/Small domain/b-strand 6 Severe perturbation during the
transition from the super-open to
closed form. Mild local structural
alteration
NOVEL
MD12/89 10 c.1339delC p.Arg447Glyfs/Small domain/a13 helix NOVEL
MD16/75 7 c.781G.T 1/deleterious p.Gly261Arg/Large domain/loop Replacement of a small and flexible
hydrophobic residue with a large
positive residue
[26]
MD18/94 4 c.449T.A 1/deleterious p.Phe150Tyr/Small domain/b-strand 5 Introduction of a polar residue in the
hydrophobic core. Perturbation of
the b-sheet
[27]
MD19
e/20
e/79 7 c.775G.A 3/deleterious p.Ala259Thr/Large domain/loop Influence on the hydrogen bond
network near the glucose-binding
cleft
[28]
MD25 2 c.210A.C 1/deleterious p.Glu70Asp/Connection/Loop
spatially near a13 helix
Weakness of salt bridge interaction
with K458 (a13 helix)
[11]
MD26/65 10 c.1258A.G 2/deleterious p.Lys420Glu/Large domain/a12 helix Loss of a salt bridge between K420
and E440
[29]
MD38 Intron 7 c.864-1G.A IVS7-1G.A [9]
MD57 5 c.562G.A 1/deleterious p.Ala188Thr/Small domain/a4 helix Substitution of a hydrophobic
residue with a polar residue
[30]
MD59 8 c.866A.G 1/deleterious p.Tyr289Cys/Large domain/a7 helix Disruption of a favorable interaction
between Y289 and M381
[9]
MD68 7 c.834G.A 1/deleterious p.Asp278Glu/Large domain/a6 helix Mild structural alteration [9]
MD69
e/70
e Intron 5 c.580-2A.T IVS5-2A.T NOVEL
MD80 6 c.667G.A 3/deleterious p.Gly223Ser/Large domain/b-strand 9 Perturbation of the b-strand [31]
MD86 Intron 8 c.1019+5G.AI V S 8 +5G.A [27]
MD90 2 c.120G.C 2/tolerated p.Glu40Asp/Large domain/a2 helix Mild structural alteration NOVEL
MD91 10 c.1345G.C 3/deleterious p.Ala449Thr/Small domain in the
closed form/a13 helix
Introduction of a larger and polar
side chain
[9]
MD95 9 c.1182_1191del p.Glu395_Arg397del/Large domain/
last residue of a11 helix and following
loop
Destabilization of the C-terminal
region of the helix and shortening
of loop
NOVEL
aGenBank: accession number (AH005826).
bThe reference cDNA sequence was obtained from GenBank (NM_000162) and +1 corresponds to the A of the ATG translation
initiation codon.
cPolyphen prediction: probably damaging (1), benign (2), possibly damaging (3). SIFT score: ,0.05 deleterious variant, $0.05 tolerated variant.
dSwissprot accession number: P35557.
eSibling pairs (MD19/20: two sisters; MD69/70: brother/sister).
doi:10.1371/journal.pone.0038906.t001
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the side chain of Arg394, which in the wild-type enzyme is
directed towards the loop, changes the orientation because of
steric interactions. This change disrupts interactions between the
side chain of Arg394 and some residues of the loop. Although the
interaction between the side chains of Arg394 and Ser433 in the
loop following the a12 helix is conserved, the binding appears to
be weakened compared with the wild-type enzyme.
Kinetic Analysis and Thermo-stability of Recombinant
GCK Mutants
To select representative mutations for a functional study to
evaluate their pathogenic significance, we considered all the
mutations found in our population in the last decade (11 and
present work) in terms of severity and location. All the selected
mutations were mapped in the whole GCK structure: p.Hi-
s137Asp, pPhe150Tyr, p.Val154Leu, p.Gly162Asp, in the small
domain, Arg303Trp and p.Arg392Ser, in the large domain and
p.Glu70Asp in a loop connecting the two domains. Three among
these mutations, (p.Gly162Asp, p.His137Asp and p.Arg392Ser)
were the most severe and none have been produced or
characterized. Figure 2 shows the position of selected mutated
residues in the structure model of the GCK enzyme. All variants
displayed reduced enzyme activity versus the wild-type GST-
GCK, as shown by the Ia index. The kinetic characteristics of
GST-GCK-wt and GST-GCK-mutants, determined in vitro
enzymatic assays, are shown in Table 2. Mutations p.Gly162Asp,
p.Phe150Tyr and p.Val154Leu, localized in the core of the
molecule, not far from the substrate binding site, produced the
strongest effect. The p.Gly162Asp change is very deleterious since
no enzymatic activity was detected in the mutant protein, and
mutations p.Phe150Tyr and p.Val154Leu reduced enzyme
activity to below 10% of the wild-type enzyme. In contrast,
mutations p.Glu70Asp, p.His137Asp, p.Arg303Trp and p.Arg392-
Ser, localized in more peripheral positions, retained at least 25%
of wild-type activity. We also evaluated the protein stability of
wild-type and of mutant GST-GCK and the time-course of
thermal inactivation at different temperatures (Figure 3A and B
respectively). Wild-type GCK activity remained practically con-
stant under temperatures up to 50uC, but fell abruptly at 55uC. In
contrast, the enzyme activity of all mutants, except GST-GCK
(p.Glu70Asp), rapidly decreased by more than 50% at 50uC
(Figure 3A). The time-course analysis of GCK thermal inactiva-
tion indicated that the mutants rendered the enzyme thermo-
unstable (more than 50% of GCK activity was lost within 30 min
at 50uC), whereas 50% of wild-type GCK activity was present
after 30 min of incubation at the critical temperature (Figure 3B).
Discussion
A correct diagnostic approach to the MODY2 patient is
important to avoid useless, expensive analyses and misclassification
of the diabetes. In this study, we characterized the GCK gene by
DHPLC followed by sequence analysis in 66 patients with
suspected MODY2 enrolled between 2006 and 2010. We
identified 19 GCK mutations in 28 children accounting for
42.4% of suspected MODY2 children. Our data are similar to
those we obtained between 2001 and 2005 [11] and are also in
agreement with the high prevalence of MODY2 (up to 61% of
MODY forms) found in Italy and in southern Europe [12,13].
Among the 19 GCK variants described herein, six are new
(p.Lys458_Cys461del, p.Val154Leu, p.Arg447Glyfs, IVS5-2A.T,
p.Glu40Asp and p.Glu395_Arg397del) and 13 previously report-
ed. Glucokinase missense mutations are the most frequent causes
of MODY2 [9]. In our study, the missense mutations (13/19: two
new and 11 known), and deletions (n =3) were distributed
throughout the protein: six/16 (38%) in the small domain, nine/
16 (56%) in the large domain and one/16 (6%) in the connecting
region of the protein. These findings are in agreement with a study
in which no hot spot mutations were reported [9].
In the attempt to understand how the detected mutations could
contribute to MODY2 insurgence, we searched for structure/
function correlations of the disease-causing mutated proteins. First,
we evaluated the impact of each mutation (except splice variants
and deletions) on the enzyme 3D-structure and then, for seven
selected mutations, we carried out functional studies. All the
mutations considered here are buried in the enzyme, except for
p.Glu70Asp that is located on the surface of the protein, and all
mutations are far from the active and ATP binding sites (Table 1).
Apart from p.Val154Leu and p.Phe150Tyr that undergo large
movements during the conformational transition from the super-
open to the closed active form, all the mutant structures exhibit
local structural alterations (Table 1) that well correlate to kinetic
parameters and thermal inactivation data (Table 2, Figure 3). In
all cases, the amino-acid replacement either provokes the loss of
stabilizing interactions or generates unfavorable interactions that
may destabilize the enzyme.
Table 2. Kinetic constants of human recombinant wild type-GCK and mutant b-cell GST-GCK fusion proteins.
Preparation
Protein yield
(mg/L of culture) Kcat (s
21)
S0.5 for glucose
(mmol/L) nH
Km for ATP
(mmol/L) Ia
Wild-type GST-GCK 3.1260.91 44.1067.50 7.2060.40 1.4060.08 0.4060.00 1.060.07
GST-GCK(Glu70Asp] 2.3560.55 27.4064.80* 20.1063.20{ 1.2060.07 0.2560.05 0.2560.06**
GST-GCK(His137Asp] 2.8260.47 17.2061.20** 18.1063.10* 1.1060.03** 0.2360.03* 0.2660.09**
GST-GCK(Phe150Tyr] 3.0760.55 9.9262.38* 101.4066.20** 1.0660.05* 3.1160.48* 0.01460.003*
GST-GCK(Val154Leu] 2.7760.48 46.6064.40 26.0063.40* 1.5460.01 1.6260.16* 0.09960.036**
GST-GCK(Gly162Asp] 2.7860.58 Undetectable activity
GST-GCK(Arg303Trp] 1.5860.26 14.6061.38** 4.6260.10** 1.5260.02 0.2960.01* 0.5960.09*
GST-GCK(Arg392Ser] 2.4460.74 41.30611.30 11.9061.70* 1.3060.03 0.6360.03* 0.6060.25
Data represent means 6 SEM of 3 separate enzyme expressions each tested in duplicate. Note that the Hill coefficient (nH) and the relative activity index (Ia) are unit
less. Kcat: GCK catalytic constant; S0.5: affinity constant for glucose; nH: Hill coefficient; Km for ATP: affinity constant for ATP; Ia: GCK activity index. (*)p,0.05, t test;
(**)p,0.005, t test.
doi:10.1371/journal.pone.0038906.t002
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of seven GCK variants distributed in different functional
domains of the enzyme: three variants described in the present
study (p.Phe150Tyr, p.Val154Leu, p.Arg303Trp) and four
(p.Glu70Asp, p.His137Asp, p.Gly162Asp and p.Arg392Ser)
previously reported [11]. The GST-GCK (p.Glu70Asp) mutant
showed a GCK activity index significantly lower than the wild
type (mean Ia=0.25). This effect is due to discrete defects in the
kinetic constants, in particular, glucose affinity was significantly
reduced (S0.5 for glucose: 20.163.2 vs 7.260.4 mM). Variant
p.Glu70Lys displayed a similarly decreased activity index (mean
Ia =0.31) without significant thermo-instability [14,15]. The
substitution of histidine with aspartic acid (p.His137Asp) affected
GCK function (mean Ia =0.26). As shown by molecular
modelling, this mutation introduces a negative charge in the
region that may affect the charge distribution of the protein [11].
The previously reported mutation p.His137Arg, in which His is
replaced by the positively charged arginine, did not affect
enzyme activity (mean Ia =0.92) [15]. This finding shows that a
negatively charged amino acid is not tolerated at this site.
p.Phe150Tyr and the novel p.Val154Leu mutations dramatically
reduced GCK activity (mean Ia =0.014 and 0.099, respectively)
Figure 1. View of the mutations p.Phe150Tyr and p.Val154Leu in the whole structures and in their local environment. A: The
structures of GCK in the super-open inactive form (PDB code code: 1v4t) and in the closed active form (PDB code code: 1v4s) are shown on the left
and on the right, respectively. In the closed form (right) the sugar is shown as a yellow stick. In both panels, the large domain is in the same
orientation and is circled. It is clear that the small domain undergoes a large conformational variation from the super-open to the closed form.
Specifically the region embodying the residues Phe150 (blue sphere) and Val154 (red sphere) dramatically changes its orientation. B: Close-up view of
the wild-type closed structure showing the hydrophobic core rich in aromatic/hydrophobic amino acids. Leu79, Phe123, Phe148, Phe150, Val154,
Leu164, Trp167 and Phe171 form an intricate network of stabilizing hydrophobic interactions. C: Structure of GCK closed structure containing the
both the Tyr150 and Leu154 mutated residues. Introduction of the oxydryl group (red) of Tyr150 within the hydrophobic core disrupts the
interactions present in the wt-enzyme. The replacement of Val154 by leucine produces only small changes in the closed form.
doi:10.1371/journal.pone.0038906.g001
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Both mutations displayed high S0.5 and ATP Km values, which
indicate a greatly reduced affinity for glucose and ATP. In
particular, the cooperativity of p.Phe150Tyr was significantly
reduced (nH =1.06 vs 1.40, t test, p =0.038). It is noteworthy
that Val154 is one of residues that undergo large movements
during the transition from the super-open to the closed form.
Even though the replacement of Val by Leu provokes only small
local perturbations, the latter may be relevant during the
conformational transition induced by ATP and glucose binding.
The substitution of glycine 162 by aspartic acid (p.Gly162Asp)
affected the hydrophobic core of the enzyme and, as predicted
by molecular modelling [11], markedly alters the structure and
dynamics of the domain. This is one of the most dramatic
mutations we identified as it introduces a net negative charge
into a hydrophobic environment [11]. In fact, the enzyme
activity of this mutant was undetectable. Although any reduction
in the Ia below 30% of the wild type would have little further
effect on the fasting plasma glucose [15], it is noteworthy that
fasting glycemia was higher in the child with this mutation
(10.0 mmol/L) [11] than in other MODY2 children (mean
6.760.8 mmol/L). Arg 303 is located in the a8 helix and
molecular modelling indicates that the Arg-to-Trp change at this
position would destabilize the helix structure. Mutation
p.Arg303Trp caused a reduction of the activity index (mean Ia
=0.59), mainly due to a decrease in the catalytic constant, being
Figure 2. Distribution of the selected GCK mutations. The structure of GCK in the active closed form is shown (PDB code: 1v4s); the small and
large domains are drawn in cyan and red, respectively; glucose appears as a yellow stick. Mutation sites are shown as green or blue spheres.
doi:10.1371/journal.pone.0038906.g002
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with the finding that other mutations in the same helix
(p.Leu309Pro and p.Arg308Trp) increased thermal inactivation
and/or modified glucose affinity [16,17]. Taken together, these
results suggest that the a8 helix plays a role in the regulation of
substrate affinity and protein stability. Mutation p.Arg392Ser is
located in the protein periphery and, like the neighboring
mutation p.Arg397Leu [17], it only slightly affected GCK
activity. Thus, our mutants reduced the enzyme’s catalytic
activity by altering one or more kinetic parameters. Moreover, all
mutants, except GCK-Glu70Asp, displayed thermal-instability,
which has been implicated in hyperglycemia in MODY2 patients
[17,18]. Nevertheless, additional defects caused by these muta-
tions on other mechanisms of GCK control, such as post-
translational regulation, interaction with other protein partners
or organelles, cannot be excluded. Globally our evaluation of
enzyme activity indicates that all seven mutants play a
pathogenic role in MODY2 insurgence. In addition although
altered glucose and ATP binding, and thermal stability appear to
be the major causes of the disease, in a few cases mutations
affected cooperativity and molecular motions, and hence
impaired enzyme activity.
Although the in vitro functional evaluation of a GCK-mutant is
a useful method with which to predict the effect exerted by a DNA
change on enzyme activity, it is not a practical approach to the
diagnosis of MODY. In our experience, taking into account all the
experimental data concerning the seven mutants expressed, we
found that the mutations induced structural alterations predicted
by modeling that were in good agreement with kinetics/
thermostability analyses. Therefore, this approach could be a
reliable surrogate to predict the pathogenic role of a GCK variant.
In conclusion, in this five-year update of GCK mutations in
MODY2 children from southern Italy, we have identified six new
GCK variants thereby expanding the MODY2 mutation panel.
Furthermore, our study, carried out by integrating DHPLC,
sequencing, bioinformatics and functional analysis, provides new
information about the structure-function relationship of human
glucokinase mutations and MODY2.
Figure 3. Effect of temperature on the stability of GST-GCK mutants. Stock enzyme solutions were diluted to 250 mg/ml in storage buffer
containing 30% glycerol, 50 mM glucose, 10 mM glutathione, 5 mM DTT, 200 mM KCl and 50 mMTris/HCl, pH 8.0. Panel A: The enzyme solutions
were incubated for 30 min at temperatures ranging from 30 to 55uC and then assayed at 30uC as described in the Methods section. Panel B: The
enzyme solutions were incubated for periods of time from 5 to 60 min at 50uC. Results are means and SEM of three independent enzyme
preparations for each mutant except for GST-GCK (Phe150Tyr) which corresponds to two independent enzyme preparations. (*) p#0.03, ({) p,0.008.
doi:10.1371/journal.pone.0038906.g003
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Ethics Approval
The study was conducted according to the Helsinki II
declaration and it was approved by the Ethics Committee of the
School of Medicine Federico II, Naples, Italy.
Written informed consent to the study was obtained from each
adult subject and from both parents of children.
Subjects
Between 2006 and 2010, 720 hyperglycemic children were
monitored at the Departments of Pediatrics of the University of
Naples ‘‘Federico II’’ and of the Second University of Naples,
Italy. Sixty-six patients (mean age 109 months, 53% girls) who had
fasting hyperglycemia (.5.5 mmol/L), HbA1c ,7.0% and a
family history of diabetes for at least two consecutive generations
were enrolled in the study as suspected MODY2 individuals. The
autoimmune markers of type-1 diabetes (glutamate decarboxylase,
protein tyrosine phosphatase-like protein and insulin antibodies)
were evaluated; the presence of more than one antibody was
considered an exclusion criterion. One hundred unrelated
euglycemic controls (mean age 363 months, 69% girls) were
recruited at CEINGE (Advanced Biotechnologies, s.c.a.r.l. Naples)
also between 2006–2010.
Patients, their mother and father, and controls provided 2 blood
samples for biochemical testing and for DNA extraction. BMIz-
score (Center for Disease Control normative, http://www.cdc.
gov), family history of diabetes and/or other diseases, birth weight
and age at admission were recorded for each patient. FPG,
triglycerides (evaluated with routine methods) and HbA1c
measure with HPLC (HLC-723 G7 TOSOH Bioscience Tokyo,
Japan) were evaluated in each suspected MODY2 child. Genomic
DNA from patients, their mother and father, and controls was
extracted with the Nucleon BACC 2 kit (Amersham Biosciences
Europe, Milan, Italy).
GCK Gene Analysis
The 10 exons, including their flanking intronic regions, of the
GCK gene were amplified using primers and PCR conditions
described elsewhere [11]. The amplified fragments were dena-
tured at 95uC for 10 min and then renatured for 10 min to
generate heteroduplices. Each fragment was run on the DHPLC
WAVE DNA fragment analysis system (Transgenomic, Inc.
Omaha, NE) using DHPLC conditions reported in Table S1.
Any additional or abnormal peak shape observed in the
chromatogram was further sequenced (ABI PRISM 3730;
Biosystems Foster City, CA, USA). All sequences were analysed
in comparison with the wild-type reference sequence
(NM_000162, http://www.ncbi.nlm.nih.gov/nuccore/
NM_000162) by the ABI Seqscape software v.2.5 (Applied
Biosystems). The mutations and variants were then numbered
according to the Human Genome Variation Society (http://www.
hgvs.org/).
Analysis of GCK Mutations
We first evaluated each detected GCK mutation by bioinfor-
matics (Polyphen and SIFT algorithms and Modeller programs).
We also examined the enzyme function of seven mutations among
the most severe found in our population in the last decade and
never characterized. The mutations for the latter study mapped in
the whole enzyme structure (small, large and loops connecting
domains).
Bioinformatic Analysis
Two free online prediction programs, Polyphen (http://
genetics.bwh.harvard.edu/pph/) and SIFT (http://sift.jcvi.org/
www/SIFT_seq_submit2.html), [1] were used to predict the effect
of GCK mutations on the protein. The Polyphen program [19] is
a tool for the prediction of the impact of an amino acid
substitution on the structure of a human protein using straight
forward physical and comparative considerations. The SIFT
program [20] tests a query sequence and uses multiple alignment
information to predict tolerated and deleterious substitutions for
every position of the query sequence. SIFT is a multistep
procedure that searches for similar sequences, chooses closely
related sequences that may share a function similar to that of the
query sequence, obtains the alignment of these chosen sequences,
and calculates normalized probabilities for all possible substitu-
tions from the alignment. Models of all mutants of GCK were
generated in silico with the Modeller 9v8 program using the active
form of the GCK crystal structure as template [2.3 A ˚, Brookhaven
Protein Database code (PDB code) 1v4s]. The inactive super-open
form (3.4 A ˚, PDB code 1v4t) was also considered for comparison.
After alignment with using BODIL [21], the query and
template sequences were used as input in the Modeller program
[22] and 20 models were generated. The most abundant
conformers of the replaced residue were selected and a simulated
annealing procedure was carried out to optimize side chain
conformations. The model that presented the best Modeller
Discrete Optimized Protein Energy (DOPE) score was selected to
be used in subsequent analyses. The initial models of selected
mutants were energy minimized with the GROningen MAchine
for Chemical Simulations (GROMACS) package using the
GROningen MOlecular Simulation (GROMOS) 43a1 force field,
to regularize the protein structure geometry. The molecules were
solvated in boxes containing simple point charge water molecules.
The energy minimization was obtained by 1000 steps of the
steepest descent method and subsequently by 1000 steps of the
conjugate gradient method. The notation used for secondary
structure was taken from Kamata et al. [8].
Production of Recombinant Wild-type and Mutant
Glutathionyl-S-transferase-glucokinase (GST-GCK)
Recombinant human wild-type beta cell GCK fused to GST
(GST-GCK) was prepared as described previously [23]. Mutations
were introduced into the GST-GCK construct by PCR using the
QuikChangeH II Site Directed Mutagenesis Kit (Stratagene, La
Jolla, CA, USA); the oligonucleotides are reported in Table S2.
Mutant constructs were checked by sequencing and digestion with
specific restriction enzymes (Table S2). Fusion proteins from E. coli
were expressed and purified as described previously [24]. Fusion
proteins were stored at a concentration of about 1 mg/ml at –
80uC in 30% glycerol, 50 mM glucose, 10 mM glutathione, 5 mM
DTT, 200 mM KCl and 50 mM Tris/HCl, pH =8.0. Protein
concentrations were determined with the Bio-Rad Protein Assay
(Bio-Rad Laboratories, GmbH Mu ¨nchen Germany), and bovine
serum albumin as standard. GST-GCK purification was verified
by Coomassie-stained SDS-PAGE as a single band of 75 kDa.
Enzymatic Assay
GCK activity was measured spectrophotometrically on a
UVIKONxl spectrophotometer (Secoman, France), using a
NADP
+-coupled assay with glucose-6-phosphate dehydrogenase.
Determination of kinetic parameters and thermal inactivation
were performed as previously described [23]. The Km for ATP
was measured at a glucose concentration near the relative S0.5
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38906values (7, 15, 8.5, 100, 20, 5 and 11 mM respectively for wild type,
p.Glu70Asp, p.His137Asp, p.Phe150Tyr, p.Val154Leu,
p.Gly162Asp, p.Arg303Trp and p.Arg392Ser). Thermal inactiva-
tion experiments were assayed at a glucose concentration of
100 mM. Results are reported as means 6 standard error of the
mean (SEM) of three independent enzyme preparations assayed at
least in duplicate.
Statistical Analysis
Variables are reported as mean6SD (continuous variables) or
mean 6SEM (categorical variables). We used the Student t test to
compare variables; significance was set at p,0.05. The SPSS
statistical software was used.
Supporting Information
Figure S1 Close-up view of the p.Lys420Glu mutation at
the inter-domain interface. The small and large domains are
drawn in cyan and red, respectively. Helix 13 is shown in orange.
Lys420 (red stick) forms a salt-bridge with Glu440 (yellow stick)
which is located in a loop connecting the two domains.
(DOCX)
Table S1 DHPLC conditions to detect GCK variants.
(DOCX)
Table S2 Primers used for site-directed mutagenesis in
GCK cDNA.
(DOCX)
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